Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
Harvard Business School
US Department of Justice

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,209,513

« Back to Dashboard

Summary for Patent: 4,209,513

Title: Tablet formulation
Abstract:A tablet suitable for use in the treatment of microbial infections, which tablet comprises from 80 to 98% (w/w) of a combination of a 2,4-diaminopyrimidine with a sulphonamide and not more than 20% (w/w) of both a granulating and a disintegrating agent, the combination having a particle size less than 40 .mu.m and the disintegrating agent having a swelling capacity greater than 5 ml/g.
Inventor(s): Torode; Allan J. (Basildon, GB2), Harden; David (Sidcup, GB2), Spence; John (Bickley, GB2)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:05/896,297
Patent Claim Types:
see list of patent claims
Dosage form;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,209,513

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom6758/74Feb 14, 1974

International Patent Family for Patent: 4,209,513

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria344915► Subscribe
AustriaA108475► Subscribe
Australia468465► Subscribe
Australia7817075► Subscribe
Belgium825496► Subscribe
Canada980688► Subscribe
Switzerland618432► Subscribe
Czechoslovakia220306► Subscribe
Cyprus1052► Subscribe
German Democratic Republic118228► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
US Department of Justice
Daiichi Sankyo
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus